Related Experiment Video
Updated: Aug 1, 2026
13:33
Infinium Assay for Large-scale SNP Genotyping Applications
Published on: November 19, 2013
An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19
W J Tamminga1, J Wemer, B Oosterhuis
1Pharma Bio-Research Group BV, Science Park, NL-9471 GP Zuidlaren, The Netherlands. WTamminga@PBR.NL
European Journal of Clinical Pharmacology
|June 22, 2001
Summary
A new method enables simultaneous phenotyping and genotyping for CYP2D6 and CYP2C19 drug metabolism. A single blood sample at 3 hours post-dose provides comprehensive individual metabolic capacity information.
Area of Science:
- Pharmacogenomics
- Drug Metabolism Studies
Background:
- CYP2D6 and CYP2C19 are crucial enzymes for drug metabolism.
- Accurate phenotyping and genotyping are essential for personalized medicine.
Purpose of the Study:
- To develop and validate a simultaneous method for phenotyping and genotyping CYP2D6 and CYP2C19.
- To establish a practical, single-sample approach for assessing drug metabolism capacity.
Main Methods:
- Six healthy volunteers (3 extensive and 3 poor CYP2D6 metabolizers) participated.
- Dextromethorphan and metoprolol were used to probe CYP2D6; omeprazole probed CYP2C19.
- High-performance liquid chromatography (HPLC) analyzed plasma drug and metabolite levels; genotyping was performed.
Main Results:
- Plasma drug levels were measurable up to 8 hours post-dose.
- A significant correlation was found between timed measurements and AUC0-12 values for metabolic ratios at 3 hours.
- The proposed method successfully assessed genotype and metabolic ratios for both enzymes.
Conclusions:
- A practical, single-sample method for simultaneous CYP2D6 and CYP2C19 phenotyping and genotyping is presented.
- Administering metoprolol (100 mg) and omeprazole (40 mg), followed by a 3-hour plasma sample, allows assessment of metabolic capacity.
- This approach provides essential information for understanding individual drug metabolism.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...